Morgan Stanley’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $39.6M | Sell |
2,202,641
-394,352
| -15% | -$7.46M | ﹤0.01% | 2459 |
|
|
2026
Q1 | $56.5M | Buy |
2,596,993
+684,358
| +36% | +$13.2M | ﹤0.01% | 1978 |
|
|
2025
Q4 | $41.2M | Sell |
1,912,635
-35,724
| -2% | -$753K | ﹤0.01% | 2280 |
|
|
2025
Q3 | $37.5M | Buy |
1,948,359
+461,433
| +31% | +$8.23M | ﹤0.01% | 2268 |
|
|
2025
Q2 | $25.4M | Sell |
1,486,926
-485,196
| -25% | -$20.7M | ﹤0.01% | 2569 |
|
|
2025
Q1 | $126M | Buy |
1,972,122
+980,467
| +99% | +$103M | 0.01% | 1088 |
|
|
2024
Q4 | $121M | Buy |
991,655
+38,551
| +4% | +$4.72M | 0.01% | 1127 |
|
|
2024
Q3 | $119M | Sell |
953,104
-1,670,257
| -64% | -$231M | 0.01% | 1118 |
|
|
2024
Q2 | $414M | Buy |
2,623,361
+1,734,928
| +195% | +$223M | 0.03% | 513 |
|
|
2024
Q1 | $115M | Sell |
888,433
-491,716
| -36% | -$60.2M | 0.01% | 1089 |
|
|
2023
Q4 | $133M | Buy |
1,380,149
+524,705
| +61% | +$50.3M | 0.01% | 977 |
|
|
2023
Q3 | $104M | Sell |
855,444
-120,906
| -12% | -$13.7M | 0.01% | 1033 |
|
|
2023
Q2 | $112M | Buy |
976,350
+86,844
| +10% | +$11.2M | 0.01% | 1019 |
|
|
2023
Q1 | $123M | Buy |
889,506
+432,453
| +95% | +$56.1M | 0.01% | 945 |
|
|
2022
Q4 | $59.2M | Buy |
457,053
+60,786
| +15% | +$7.04M | 0.01% | 1368 |
|
|
2022
Q3 | $43.8M | Sell |
396,267
-21,439
| -5% | -$2.16M | 0.01% | 1427 |
|
|
2022
Q2 | $31.3M | Buy |
417,706
+47,190
| +13% | +$3.47M | ﹤0.01% | 1797 |
|
|
2022
Q1 | $28.9M | Buy |
370,516
+133,013
| +56% | +$10.2M | ﹤0.01% | 1740 |
|
|
2021
Q4 | $21.4M | Sell |
237,503
-101,766
| -30% | -$8.7M | ﹤0.01% | 2081 |
|
|
2021
Q3 | $31.4M | Buy |
339,269
+14,573
| +4% | +$1.12M | ﹤0.01% | 1668 |
|
|
2021
Q2 | $25.2M | Buy |
324,696
+132,095
| +69% | +$10M | ﹤0.01% | 1903 |
|
|
2021
Q1 | $14.4M | Sell |
192,601
-103,755
| -35% | -$9.57M | ﹤0.01% | 2273 |
|
|
2020
Q4 | $50.5M | Buy |
296,356
+92,845
| +46% | +$13.8M | 0.01% | 1096 |
|
|
2020
Q3 | $28.6M | Sell |
203,511
-8,169
| -4% | -$1.24M | 0.01% | 1218 |
|
|
2020
Q2 | $33.9M | Sell |
211,680
-128,831
| -38% | -$17.5M | 0.01% | 1065 |
|
|
2020
Q1 | $33.3M | Buy |
340,511
+51,082
| +18% | +$5.84M | 0.01% | 958 |
|
|
2019
Q4 | $37.3M | Buy |
289,429
+80,818
| +39% | +$8.16M | 0.01% | 1140 |
|
|
2019
Q3 | $15.7M | Sell |
208,611
-65,789
| -24% | -$7.77M | ﹤0.01% | 1685 |
|
|
2019
Q2 | $41.7M | Buy |
274,400
+110,095
| +67% | +$13.4M | 0.01% | 950 |
|
|
2019
Q1 | $19.6M | Sell |
164,305
-2,877
| -2% | -$370K | 0.01% | 1463 |
|
|
2018
Q4 | $18.2M | Sell |
167,182
-21,393
| -11% | -$2.68M | 0.01% | 1538 |
|
|
2018
Q3 | $30.5M | Sell |
188,575
-121,631
| -39% | -$16.6M | 0.01% | 1312 |
|
|
2018
Q2 | $41M | Sell |
310,206
-212,378
| -41% | -$20M | 0.01% | 1027 |
|
|
2018
Q1 | $38.7M | Sell |
522,584
-305,453
| -37% | -$20.4M | 0.01% | 1097 |
|
|
2017
Q4 | $46.1M | Buy |
828,037
+566,915
| +217% | +$30M | 0.01% | 1005 |
|
|
2017
Q3 | $11.8M | Buy |
261,122
+82,938
| +47% | +$3.31M | ﹤0.01% | 2104 |
|
|
2017
Q2 | $6.01M | Sell |
178,184
-11,926
| -6% | -$388K | ﹤0.01% | 2664 |
|
|
2017
Q1 | $5.63M | Sell |
190,110
-19,174
| -9% | -$593K | ﹤0.01% | 2746 |
|
|
2016
Q4 | $5.74M | Sell |
209,284
-274,263
| -57% | -$11M | ﹤0.01% | 2849 |
|
|
2016
Q3 | $29.7M | Sell |
483,547
-484,180
| -50% | -$14.6M | 0.01% | 1167 |
|
|
2016
Q2 | $18.5M | Buy |
967,727
+522,049
| +117% | +$9.67M | 0.01% | 1483 |
|
|
2016
Q1 | $8.7M | Buy |
445,678
+311,893
| +233% | +$5.45M | ﹤0.01% | 1983 |
|
|
2015
Q4 | $5.16M | Buy |
133,785
+24,477
| +22% | +$794K | ﹤0.01% | 2635 |
|
|
2015
Q3 | $3.51M | Sell |
109,308
-11,753
| -10% | -$399K | ﹤0.01% | 2961 |
|
|
2015
Q2 | $3.68M | Buy |
121,061
+48,123
| +66% | +$984K | ﹤0.01% | 3060 |
|
|
2015
Q1 | $969K | Buy |
72,938
+1,102
| +2% | +$14.7K | ﹤0.01% | 4155 |
|
|
2014
Q4 | $1.04M | Sell |
71,836
-29,493
| -29% | -$499K | ﹤0.01% | 4120 |
|
|
2014
Q3 | $2.14M | Sell |
101,329
-8,447
| -8% | -$191K | ﹤0.01% | 3380 |
|
|
2014
Q2 | $3.27M | Buy |
109,776
+22,930
| +26% | +$725K | ﹤0.01% | 3066 |
|
|
2014
Q1 | $2.09M | Buy |
86,846
+29,782
| +52% | +$759K | ﹤0.01% | 3375 |
|
|
2013
Q4 | $1.16M | Sell |
57,064
-282,756
| -83% | -$8.4M | ﹤0.01% | 3811 |
|
|
2013
Q3 | $16.1M | Buy |
339,820
+266,087
| +361% | +$10.2M | 0.01% | 1405 |
|
|
2013
Q2 | $2.8M | Buy |
+73,733
| New | +$2.64M | ﹤0.01% | 2867 |
|
Other funds holding SRPT
EAM
Morgan Stanley's SRPT Position: Q2 2026 in Review
Morgan Stanley reduced its Sarepta Therapeutics (SRPT) stake by 15% in Q2 2026, selling an estimated $7.46M and leaving 2,202,641 shares worth $39.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2459.
Morgan Stanley first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $414M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Morgan Stanley held 2,202,641 shares of Sarepta Therapeutics worth $39.6M as of Q2 2026.
- Morgan Stanley sold 394,352 Sarepta Therapeutics shares in Q2 2026, an estimated $7.46M.
- Sarepta Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2459 holding.
- Morgan Stanley first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Morgan Stanley's Sarepta Therapeutics position peaked at $414M in Q2 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.